{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:02Z","timestamp":1760144222630,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"New York Medical College"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Purpose: To determine the impact of booster COVID-19 vaccination on SARS-CoV-2 symptoms. Background: The Omicron surge of infections provided an opportunity to evaluate symptoms in relation to booster receipt. Methods: At a US medical college, the number, type, and duration of symptoms were evaluated for 476 students or employees, factoring in days between last vaccination and SARS-CoV-2 diagnosis. Results: Compared with vaccinated non-boosted individuals, boosted individuals reported a significantly higher frequency of nasal congestion (57.9% vs. 44.4%, p = 0.018) and nasal congestion and\/or sore throat (77.2% vs. 62.0%, p = 0.003); in contrast, the frequency of body\/muscle aches was significantly less among boosted individuals (22.1% vs. 32.4%, p = 0.038). With each one week increase in time since booster receipt, the probability of fever increased significantly by 4.4% (OR 1.044, 95% CI 1.01, 1.07, p = 0.001), and the probability of cough increased significantly by 4.8% (OR 1.048, 95% CI 1.01, 10.8, p= 0.010). Conclusions: Within a medical college population, during the first 7 months of the Omicron surge of infections, compared with vaccinated non-boosted individuals, boosted individuals significantly more often reported the following: nasal congestion as well as nasal congestion and\/or sore throat. In contrast, body\/muscle aches were reported significantly less often. The rates of fever and cough each significantly increased as time since booster dose receipt increased. These data suggest that having had a booster vaccination, as well the timing of receiving it, impacts the clinical manifestations of breakthrough SARS-CoV-2 infections. Additional studies are needed to precisely define SARS-CoV-2 symptoms in relation to booster vaccinations.<\/jats:p>","DOI":"10.3390\/vaccines12030327","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:36:31Z","timestamp":1710822991000},"page":"327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 Symptoms during the Omicron Surge Differ between Boosted and Vaccinated Non-Boosted Persons"],"prefix":"10.3390","volume":"12","author":[{"given":"Marisa A.","family":"Montecalvo","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA"},{"name":"Department of Health Services, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Visintainer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Massachusetts Chan Medical School\u2013Baystate, Springfield, MA 01119, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-617X","authenticated-orcid":false,"given":"Elizabeth","family":"Drugge","sequence":"additional","affiliation":[{"name":"Department of Public Health, Division of Epidemiology, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Department of Health Services, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Raffa","sequence":"additional","affiliation":[{"name":"Department of Health Services, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"McKenna","sequence":"additional","affiliation":[{"name":"Department of Health Services, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Moronta","sequence":"additional","affiliation":[{"name":"Department of Health Services, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.15585\/mmwr.mm7031e2","article-title":"Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings\u2014Barnstable County, Massachusetts","volume":"70","author":"Brown","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"COVID-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMc2112981","article-title":"Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce","volume":"385","author":"Keehner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2022, October 05). American College of Immunization Practices Meeting. 23 September 2021, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-9-23\/03-COVID-Oliver.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jama.2021.24868","article-title":"Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves","volume":"327","author":"Maslo","year":"2022","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2022.2274","article-title":"Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada","volume":"327","author":"Ulloa","year":"2022","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California","volume":"28","author":"Lewnard","year":"2022","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the Omicron variant from previous SARS-CoV-2 infection","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMc2201821","article-title":"Protection with a third dose of mRNA vaccine against SARS-CoV-2 variants in frontline workers","volume":"386","author":"Yoon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","unstructured":"New York State Department of Health (2021). Health Advisory: COVID-19 Vaccine Boosters Recommended for All Adults."},{"key":"ref_15","unstructured":"New York State Department of Health (2022, December 20). Interim Updated Isolation & Quarantine Guidance, 4 January 2022, Available online: https:\/\/coronavirus.health.ny.gov\/system\/files\/documents\/2022\/01\/nys_updated_isolation_quarantine_guidance_01042022.pdf."},{"key":"ref_16","unstructured":"Centers for Disease Control and Prevention (2022, February 01). Use of COVID-19 Vaccines in the United States, Interim Clinical Considerations, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#covid-vaccines."},{"key":"ref_17","unstructured":"Reddy, S. (2023, May 29). Interim Clinical Considerations for Moderna and Janssen COVID-19 Vaccine Booster Doses, Presented at the American College of Immunization Practices Meeting, 21 October 2021, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/12-COVID-Reddy-508.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1017\/ice.2022.105","article-title":"Comparison of coronavirus disease 2019 (COVID-19) symptoms at diagnosis among healthcare personnel before and after the emergence of the omicron variant","volume":"44","author":"Laracy","year":"2022","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.2022.J067","article-title":"COVID-19 related symptoms during the SARS-CoV-2 Omicron (B.1.1.529) variant surge in Japan","volume":"258","author":"Akaishi","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2235844","DOI":"10.1001\/jamanetworkopen.2022.35844","article-title":"COVID-19 symptoms and duration of rapid antigen test positivity at a community testing and surveillance site during pre-Delta, Delta, and Omicron BA.1 periods","volume":"5","author":"Marquez","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_21","first-page":"e133","article-title":"Omicron-associated changes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms in the United Kingdom","volume":"76","author":"Vihta","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3201\/eid2807.220470","article-title":"University-associated SARS-CoV-2 Omicron BA.2 infections, Maricopa County, Arizona, USA, 2022","volume":"28","author":"Fowle","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/infdis\/jiac113","article-title":"Why does the Omicron variant largely spare olfactory function? Implications for the pathogenesis of anosmia in coronavirus disease 2019","volume":"226","author":"Butowt","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Miyauchi, S., Hiyama, T., Nakano, Y., Yoshida, M., Yoshino, A., Miyake, Y., and Okamoto, Y. (2022). Real world effectiveness of a booster dose of the COVID-19 vaccines among Japanese university students. Vaccines, 10.","DOI":"10.3390\/vaccines10081283"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Flury, B.B., G\u00fcsewell, S., Egger, T., Leal, O., Brucher, A., Lemmenmeier, E., Meier Kleeb, D., M\u00f6ller, J.C., Rieder, P., and R\u00fctti, M. (2022). Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland- A multicenter cohort study. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1004125"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"The Heroes Recover Network (2022). Association of mRNA vaccination with clinical and virologic features of COVID-19 among US essential and frontline workers. JAMA, 328, 1523\u20131533.","DOI":"10.1001\/jama.2022.18550"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M20-1281","article-title":"The role of medical students during the COVID-19 pandemic","volume":"173","author":"Miller","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"COVID-19 Vaccines\u2014Immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/ciac785","article-title":"Effectiveness of messenger RNA-1273 booster against coronavirus disease 2019 in immunocompetent adults","volume":"76","author":"Florea","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/infdis\/jiac419","article-title":"Effectiveness of mRNA booster vaccination against mild, moderate and severe COVID-19 caused by Omicron variant in a large, population-based Norwegian cohort","volume":"226","author":"Laake","year":"2022","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:15:46Z","timestamp":1760105746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["vaccines12030327"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12030327","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}